Bio-Rad Laboratories ( (BIO) ) has released its Q1 earnings. Here is a breakdown of the information Bio-Rad Laboratories presented to its investors.
Bio-Rad Laboratories, Inc., headquartered in Hercules, California, is a prominent player in the life science research and clinical diagnostics sectors, known for its innovative products that cater to universities, research institutions, hospitals, and biopharmaceutical companies globally.
In its first-quarter 2025 financial results, Bio-Rad Laboratories reported a decrease in revenue to $585.4 million, down from $610.8 million in the same period of 2024. Despite the challenging market conditions, the company maintained solid margins through strategic expense management and focused execution.
Key financial metrics revealed a decline in both the Life Science and Clinical Diagnostics segments, with sales dropping by 5.4% and 3.2% respectively. The company’s net income also saw a significant decrease from $383.9 million in Q1 2024 to $64.0 million in Q1 2025, largely influenced by changes in the fair market value of its investment in Sartorius AG. However, on a non-GAAP basis, net income rose to $71.0 million from $65.3 million in the previous year, reflecting improved operational efficiencies.
Looking ahead, Bio-Rad has adjusted its financial outlook for the full year 2025, anticipating a non-GAAP, currency-neutral revenue change ranging from a 1.0% decline to a 1.5% growth. The company remains committed to advancing its growth and margin expansion initiatives amidst evolving macroeconomic conditions.